"""
Question: 1101 

Evidence: Here, the 3 year resistance analysis and impact of baseline resistance substitutions on treatment response are described. Here we assessed the impact of pre-existing drug resistance substitutions on treatment outcomes and emergent resistance in an integrated analysis of both studies.

Rationale: The abstract and introduction state that this paper newly describes a three-year resistance analysis and assesses the impact of baseline substitutions in an integrated analysis, indicating presentation of analyses not previously published.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples from all randomized and treated participants.

Rationale: The methods clearly describe obtaining and analyzing HIV-1 sequences (population sequencing and NGS) of PR, RT, and IN from study participants.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Study 1489 and Study 1490 are Phase 3, randomized, double-blind, multicentre, active-control studies evaluating the safety and efficacy of B/F/TAF. Resistance analyses were performed on participants with confirmed viral rebound of HIV-1 RNA 200 copies/mL through Week 144 or last visit who did not resuppress.

Rationale: The paper focuses on clinical trial participants and on-resistance testing of clinical samples; it does not describe any laboratory in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed at Monogram Biosciences. No participant in any treatment group developed treatment-emergent genotypic or phenotypic resistance to study drugs.

Rationale: Phenotypic testing is an in vitro susceptibility assessment; the paper reports such testing and its result (no emergent phenotypic resistance).

Answer: Yes
"""

"""
Question: 2101 

Evidence: Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples from all randomized and treated participants.

Rationale: Although sequencing was performed, the paper does not mention depositing sequences or provide any GenBank accession numbers.

Answer: No
"""

"""
Question: 2102 

Evidence: Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples from all randomized and treated participants.

Rationale: The paper contains no GenBank accession numbers for any sequenced isolates (clinical or laboratory); therefore it does not report accession numbers for non-laboratory isolates.

Answer: No
"""

"""
Question: 2103 

Evidence: Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples from all randomized and treated participants.

Rationale: No GenBank accession numbers are provided anywhere in the text.

Answer: NA
"""

"""
Question: 2202 

Evidence: Retrospective PR, RT, and IN deep sequencing analyses of the 1274 enrolled participants' baseline samples were performed, and resistance mutations at frequencies ≥15% were combined with population sequencing results (Tables 1 and 2). This included one participant in the B/F/TAF group with the INSTI resistance substitutions Q148H+G140S and K70R and K103N in RT.

Rationale: The paper presents aggregate counts of specific mutations and a single illustrative case, but it does not provide per-individual mutation lists for all sequenced isolates.

Answer: No
"""

"""
Question: 2301 

Evidence: Two Phase 3, randomized, double-blind, active-controlled studies of initial HIV-1 treatment demonstrated that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was non-inferior to comparator regimens. Overall, treatment with B/F/TAF, DTG/ABC/3TC, or DTG+F/TAF led to high rates of durable virological suppression in HIV-1 treatment-naive participants.

Rationale: The paper repeatedly specifies HIV-1 as the species under study.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: HIV-1 subtype B was predominant in all treatment groups. Retrospective baseline IN genotypic data was obtained by deep sequencing for 1270 of 1274 participants.

Rationale: The only subtype information provided is that subtype B predominated; other subtypes are not enumerated.

Answer: Subtype B predominated
"""

"""
Question: 2303 

Evidence: Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples.

Rationale: The sequenced genes are PR (protease), RT (reverse transcriptase), and IN (integrase).

Answer: Protease, reverse transcriptase, integrase
"""

"""
Question: 2304 

Evidence: Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples.

Rationale: PR, RT, and IN are parts of the HIV-1 pol gene; thus the paper reports results of pol gene sequencing.

Answer: Yes
"""

"""
Question: 2401 

Evidence: The studies are being conducted at 167 sites located in Australia, Europe, Latin America, and North America. Detailed methods have been published previously.

Rationale: The geographic regions for participant recruitment (and thus sequence origin) are explicitly listed.

Answer: Australia, Europe, Latin America, and North America
"""

"""
Question: 2402 

Evidence: The studies are being conducted at 167 sites located in Australia, Europe, Latin America, and North America. Open-label extensions will evaluate B/F/TAF in all participants for 96 weeks after completion of the blinded phase.

Rationale: The paper does not provide calendar years for sample collection; it only describes study phases and durations.

Answer: NA
"""

"""
Question: 2502 

Evidence: For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed at Monogram Biosciences. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples.

Rationale: The paper mentions population sequencing but does not explicitly state Sanger sequencing; therefore it cannot be confirmed from the text.

Answer: NA
"""

"""
Question: 2503 

Evidence: A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples from all randomized and treated participants in these studies using the deepType HIV assay. For this analysis, resistance substitutions were analysed at a mutation frequency cutoff of ≥15%.

Rationale: The methods explicitly state use of next-generation (deep) sequencing.

Answer: Yes
"""

"""
Question: 2504 

Evidence: Population sequencing and phenotyping were performed at Monogram Biosciences. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples.

Rationale: There is no mention of cloning samples prior to sequencing.

Answer: NA
"""

"""
Question: 2505 

Evidence: Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples.

Rationale: The paper describes population sequencing and deep sequencing, not single genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples.

Rationale: Molecular cloning is not described; therefore it cannot be confirmed.

Answer: NA
"""

"""
Question: 2601 

Evidence: The sample from the confirmation visit was analysed for resistance development if the HIV-1 RNA value was ≥200 copies/mL. For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed.

Rationale: Resistance analyses were performed on samples defined by plasma HIV-1 RNA thresholds, indicating plasma virus sequencing.

Answer: Yes
"""

"""
Question: 2602 

Evidence: The sample from the confirmation visit was analysed for resistance development if the HIV-1 RNA value was ≥200 copies/mL. For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed.

Rationale: The focus is on HIV-1 RNA (plasma) samples; PBMC or proviral DNA sequencing is not described.

Answer: No
"""

"""
Question: 2603 

Evidence: Retrospective PR, RT, and IN deep sequencing analyses of the 1274 enrolled participants' baseline samples were performed. Retrospective baseline IN genotypic data was obtained by deep sequencing for 1270 of 1274 participants.

Rationale: Baseline sequencing was conducted on all 1274 enrolled participants (with IN data available for 1270); thus 1274 plasma baseline samples were sequenced.

Answer: 1274
"""

"""
Question: 2604 

Evidence: The sample from the confirmation visit was analysed for resistance development if the HIV-1 RNA value was ≥200 copies/mL. Retrospective PR, RT, and IN deep sequencing analyses of the 1274 enrolled participants' baseline samples were performed.

Rationale: The paper does not report PBMC virus sequencing; no count is provided.

Answer: NA
"""

"""
Question: 2605 

Evidence: Participants with HIV-1 RNA ≥200 copies/mL who were on study drugs, experienced virological rebound, and did not re-suppress were included in the resistance analysis population. The sample from the confirmation visit was analysed for resistance development if the HIV-1 RNA value was ≥200 copies/mL.

Rationale: Sequencing was performed on samples with measurable plasma HIV-1 RNA, indicating active replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: The sample from the confirmation visit was analysed for resistance development if the HIV-1 RNA value was ≥200 copies/mL. For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed.

Rationale: The sequencing targeted HIV-1 RNA samples; there is no indication of sequencing from proviral DNA reservoirs.

Answer: No
"""

"""
Question: 2701 

Evidence: The clinical studies in treatment-naive participants GS-US-380-1489 (Study 1489) and GS-US-380-1490 (Study 1490) are 144 week Phase 3 studies evaluating the safety and efficacy of B/F/TAF in HIV-1-infected adults. 

Rationale: The participants were adults; infants or children are not included.

Answer: No
"""

"""
Question: 2702 

Evidence: Study 1489 and Study 1490 are Phase 3, randomized, double-blind, multicentre, active-control studies. The studies are being conducted at 167 sites located in Australia, Europe, Latin America, and North America.

Rationale: Participants were enrolled in Phase 3 clinical trials.

Answer: Yes
"""

"""
Question: 2703 

Evidence: Study 1489 and Study 1490 are Phase 3, randomized, double-blind, multicentre, active-control studies evaluating the safety and efficacy of B/F/TAF in 1274 treatment-naive HIV-1-infected participants. 

Rationale: All individuals analyzed are participants in these Phase 3 studies.

Answer: Yes
"""

"""
Question: 3101 

Evidence: Retrospective PR, RT, and IN deep sequencing analyses of the 1274 enrolled participants' baseline samples were performed. Retrospective baseline IN genotypic data was obtained by deep sequencing for 1270 of 1274 participants.

Rationale: Sequencing was performed on baseline samples from all 1274 enrolled participants (with IN sequencing successful in 1270).

Answer: 1274
"""

"""
Question: 3102 

Evidence: A retrospective next-generation sequencing/deep sequencing analysis of HIV-1 PR, RT, and IN was additionally conducted on baseline samples from all randomized and treated participants. Population sequencing data was available for all these participants.

Rationale: All enrolled participants underwent sequencing (population sequencing plus retrospective deep sequencing), though IN deep sequencing was unavailable for 4 participants; overall, sequencing was performed for all.

Answer: Yes
"""

"""
Question: 4101 

Evidence: Overall, treatment with B/F/TAF, DTG/ABC/3TC, or DTG+F/TAF led to high rates of durable virological suppression in HIV-1 treatment-naive participants. The clinical studies in treatment-naive participants GS-US-380-1489 and GS-US-380-1490 are 144 week Phase 3 studies.

Rationale: The study population was ART-naive, and sequencing was performed on these participants.

Answer: Yes
"""

"""
Question: 4102 

Evidence: The clinical studies in treatment-naive participants GS-US-380-1489 and GS-US-380-1490 are 144 week Phase 3 studies. Participants were required to show pretreatment genotypic susceptibility to study NRTIs.

Rationale: The paper focuses on treatment-naive participants; it does not include ART-experienced individuals.

Answer: No
"""

"""
Question: 4103 

Evidence: The clinical studies in treatment-naive participants GS-US-380-1489 and GS-US-380-1490 are 144 week Phase 3 studies. 

Rationale: Only ART-naive individuals were included; no ART-experienced group was sequenced.

Answer: No
"""

"""
Question: 4104 

Evidence: Retrospective PR, RT, and IN deep sequencing analyses of the 1274 enrolled participants' baseline samples were performed. 

Rationale: All 1274 enrolled participants were ART-naive; therefore 1274 samples from ART-naive individuals were obtained.

Answer: 1274
"""

"""
Question: 4105 

Evidence: The clinical studies in treatment-naive participants GS-US-380-1489 and GS-US-380-1490 are 144 week Phase 3 studies. Participants were required to show pretreatment genotypic susceptibility to emtricitabine and tenofovir alafenamide (and additional drugs depending on study).

Rationale: All participants were treatment-naive, providing complete prior ART history status (no prior ART) for the cohort.

Answer: Yes
"""

"""
Question: 4201 

Evidence: Transmitted primary drug resistance substitutions were present in the following proportions of participants: integrase strand transfer inhibitor (INSTI) resistance (-R) in 1.3% (17/1270) of participants; NRTI-R in 2.7% (35/1274); NNRTI-R in 14.1% (179/1274); and PI-R in 3.5% (44/1274). These pre-existing resistance substitutions not associated with study drug did not affect treatment outcomes.

Rationale: The paper quantifies the prevalence of transmitted drug resistance across drug classes.

Answer: Yes
"""

"""
Question: 4202 

Evidence: The impact of pretreatment resistance substitutions on treatment outcomes was assessed at Week 144. Primary NRTI resistance substitutions were observed in 2.7% (35/1274) of participants; Primary NNRTI resistance substitutions were observed in 14.1% (180/1274); Primary PI resistance substitutions were observed in 3.5% (44/1274).

Rationale: The paper reports the prevalence of pretreatment (baseline) HIV drug resistance.

Answer: Yes
"""

"""
Question: 4301 

Evidence: The INSTI bictegravir has been co-formulated in a single tablet regimen with the two nucleoside/tide reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide (B/F/TAF). Study 1489 compared B/F/TAF to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) and Study 1490 compared B/F/TAF to dolutegravir plus F/TAF (DTG+F/TAF).

Rationale: Participants received integrase inhibitors (bictegravir or dolutegravir) with NRTIs (FTC/TAF or ABC/3TC).

Answer: Integrase inhibitors and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
"""

"""
Question: 4302 

Evidence: The INSTI bictegravir (BIC; B) is co-formulated with emtricitabine and tenofovir alafenamide (B/F/TAF). Study 1489 compared B/F/TAF to dolutegravir/abacavir/lamivudine and Study 1490 compared B/F/TAF to dolutegravir plus F/TAF.

Rationale: The regimens included integrase inhibitors (bictegravir or dolutegravir).

Answer: Yes
"""

"""
Question: 4303 

Evidence: Study 1489 compared B/F/TAF to dolutegravir/abacavir/lamivudine and Study 1490 compared B/F/TAF to dolutegravir plus F/TAF. 

Rationale: None of the study regimens included protease inhibitors; the paper only discusses pre-existing PI resistance at baseline.

Answer: No
"""

"""
Question: 4304 

Evidence: Study 1489 compared B/F/TAF to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) and Study 1490 compared B/F/TAF to dolutegravir plus F/TAF (DTG+F/TAF). 

Rationale: Participants were randomized to different regimens; not everyone received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: The clinical studies in treatment-naive participants GS-US-380-1489 and GS-US-380-1490 are 144 week Phase 3 studies. Primary INSTI resistance substitutions were infrequent and were observed in 1.3% (17/1270) of participants.

Rationale: Participants had no prior ART exposure, hence they were INSTI-naive despite some having transmitted INSTI mutations.

Answer: Yes
"""

"""
Question: 4403 

Evidence: Study 1489 and Study 1490 are Phase 3, randomized, double-blind, multicentre, active-control studies evaluating the safety and efficacy of B/F/TAF. Open-label extensions will evaluate B/F/TAF in all participants for 96 weeks after completion of the blinded phase.

Rationale: The paper does not report regimen switches or counts of individuals receiving more than one regimen.

Answer: NA
"""

"""
Question: 4404 

Evidence: Study 1489 and Study 1490 are Phase 3, randomized, double-blind, multicentre, active-control studies evaluating the safety and efficacy of B/F/TAF. 

Rationale: There is no information about individuals receiving more than two ART regimens.

Answer: NA
"""

"""
Question: 4405 

Evidence: Study 1489 compared B/F/TAF to dolutegravir/abacavir/lamivudine and Study 1490 compared B/F/TAF to dolutegravir plus F/TAF. 

Rationale: The number of regimens per individual is not specified; thus whether all received the same number is not reported.

Answer: NA
"""

"""
Question: 4406 

Evidence: Study 1489 compared B/F/TAF to dolutegravir/abacavir/lamivudine and Study 1490 compared B/F/TAF to dolutegravir plus F/TAF. 

Rationale: The paper does not explicitly state that all individuals received only one regimen throughout; regimen switches are not discussed.

Answer: NA
"""

"""
Question: 4501 

Evidence: Table 1 shows the study groups as B/F/TAF (N=634), DTG/ABC/3TC (N=315), and DTG+F/TAF (N=325). Study 1489 compared B/F/TAF to dolutegravir/abacavir/lamivudine and Study 1490 compared B/F/TAF to dolutegravir plus F/TAF.

Rationale: Participants receiving dolutegravir were in the DTG/ABC/3TC (315) and DTG+F/TAF (325) groups, totaling 640.

Answer: 640
"""

"""
Question: 4502 

Evidence: Study 1489 compared B/F/TAF to dolutegravir/abacavir/lamivudine and Study 1490 compared B/F/TAF to dolutegravir plus F/TAF. 

Rationale: Darunavir (a protease inhibitor) was not part of any study regimen.

Answer: 0
"""

"""
Question: 5101 

Evidence: Overall, 98% (242/247) of participants with transmitted drug resistance substitutions versus 97% (991/1019) without any resistance substitutions achieved HIV-1 RNA <50 copies/mL at Week 144 by LOCF. 

Rationale: The numerator/denominator indicate that 247 participants had one or more transmitted drug resistance substitutions.

Answer: 247
"""

"""
Question: 5102 

Evidence: Primary INSTI resistance substitutions were infrequent and were observed in 1.3% (17/1270) of participants. The presence of the primary INSTI resistance substitutions was confirmed by standard population sequencing for Q148H + G140S and 14 of 16 T97A samples.

Rationale: The text explicitly provides the count of participants with primary INSTI resistance mutations.

Answer: 17
"""

"""
Question: 5103 

Evidence: Deep sequencing with a conservative threshold of 15% found the tenofovir alafenamide and abacavir drug resistance substitution K65R/E in three participants (two with K65E in the B/F/TAF group; frequencies of 15% to 23%). 

Rationale: K65R/E confers resistance to tenofovir; the paper reports three participants with K65R/E at baseline.

Answer: 3
"""

"""
Question: 5104 

Evidence: In total, 21 participants qualified for resistance testing; none had emergent resistance to study drugs. No participant in any treatment group developed treatment-emergent genotypic or phenotypic resistance to study drugs.

Rationale: The paper states there were no treatment-emergent resistance mutations; thus no INSTI-resistance mutations developed on therapy.

Answer: None
"""

"""
Question: 6101 

Evidence: For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed at Monogram Biosciences. 

Rationale: The phenotypic susceptibility testing was performed at Monogram Biosciences; the specific assay name is not provided.

Answer: Phenotyping performed at Monogram Biosciences (assay not specified)
"""

"""
Question: 6102 

Evidence: For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed at Monogram Biosciences. No participant in any treatment group developed treatment-emergent genotypic or phenotypic resistance to study drugs.

Rationale: The paper reports phenotypic resistance outcomes but does not present IC50/IC90 values.

Answer: No
"""

"""
Question: 6103 

Evidence: For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed at Monogram Biosciences. No participant in any treatment group developed treatment-emergent genotypic or phenotypic resistance to study drugs.

Rationale: No fold-change in IC50 values are reported.

Answer: No
"""

"""
Question: 6104 

Evidence: For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed at Monogram Biosciences. 

Rationale: The paper does not name the specific phenotypic assay used.

Answer: NA
"""

"""
Question: 6105 

Evidence: Objectives and methods focus on resistance substitutions, genotyping, and phenotyping. No participant in any treatment group developed treatment-emergent genotypic or phenotypic resistance to study drugs.

Rationale: The paper does not mention replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: For post-baseline resistance analyses of participants in the RAP, the failure and baseline samples had PR, RT, and integrase (IN) population genotyping and phenotyping performed at Monogram Biosciences. No participant in any treatment group developed treatment-emergent genotypic or phenotypic resistance to study drugs.

Rationale: The specific drugs tested in phenotypic assays are not enumerated.

Answer: NA
"""

"""
Question: 7101 

Evidence: Study 1489 and Study 1490 are Phase 3, randomized, double-blind, multicentre, active-control studies evaluating the safety and efficacy of B/F/TAF. Resistance analyses were performed on participants with confirmed viral rebound and on baseline samples.

Rationale: The paper analyzes clinical samples; it does not describe constructing site-directed mutant isolates.

Answer: No
"""

"""
Question: 7102 

Evidence: Study 1489 and Study 1490 are Phase 3, randomized, double-blind, multicentre, active-control studies. Resistance analyses were performed on participant samples defined by HIV-1 RNA criteria.

Rationale: The study does not report any in vitro passage experiments; all data are from clinical samples.

Answer: No
"""